Allogeneic CD34+ selected hematopoietic stem cell boost following CAR T-cell therapy in a patient with prolonged cytopenia and active infection

Article Hematology

Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study

Nico Gagelmann et al.

Summary: Hematotoxicity after CAR-T therapy can be managed with hematopoietic stem cell boost (HSCB), which showed a quick response and improved outcomes for sustained moderate to severe neutropenia. 31 patients received HSCB, with an overall neutrophil response rate of 84% and a median response time of 9 days. Patients with shorter duration of neutropenia had significantly better survival outcomes compared to those with longer duration. The 1-year overall survival rate was 59%.

BLOOD ADVANCES (2023)

添加到收藏夹

Article Hematology

Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy

Krishna R. Juluri et al.

Summary: CD19-targeted CAR T-cell therapy has shown significant efficacy in patients with B-cell malignancies, but is associated with toxicities such as CRS and neurotoxicity. Research suggests that the severity of CRS and prelymphodepletion platelet count are independent predictors of hematologic toxicity.

BLOOD ADVANCES (2022)

添加到收藏夹

Letter Hematology

CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy

Khushnuma Mullanfiroze et al.

BLOOD ADVANCES (2022)

添加到收藏夹

Letter Hematology

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy

Kai Rejeski et al.

BLOOD ADVANCES (2022)

添加到收藏夹

Article Hematology

CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma

Kai Rejeski et al.

Summary: Hematotoxicity is a common adverse event in CAR T-cell therapy, with baseline thrombocytopenia and hyperferritinemia being significant predictive markers. The CAR-HEMATOTOX model can accurately predict the occurrence of severe neutropenia.

BLOOD (2021)

添加到收藏夹

Review Hematology

Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis

Moazzam Shahzad et al.

Summary: Through analysis of 7 related studies, this research found that CD34-selected stem cell boost (SCB) can effectively improve the treatment outcomes of patients with Poor Graft Function (PGF) after allogeneic hematopoietic stem cell transplantation (allo-HSCT), increasing hematologic complete response (CR) and overall response rate (ORR), and potentially enhancing overall survival rate.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

添加到收藏夹

Article Hematology